Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications

Majority of clear cell renal cell carcinomas (ccRCCs) are diagnosed in the advanced metastatic stage resulting in dramatic decrease of patient survival. Thereby, early detection and monitoring of the disease may improve prognosis and treatment results. Recent technological advances enable the identi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2013-12, Vol.341 (2), p.111-126
Main Authors: Rydzanicz, Małgorzata, Wrzesiński, Tomasz, Bluyssen, Hans A.R, Wesoły, Joanna
Format: Article
Language:English
Subjects:
biomarkers
carcinoma
Carcinoma, Renal Cell - diagnosis
Carcinoma, Renal Cell - genetics
Chromosomal aberrations
chromosome aberrations
Clear cell renal cell carcinoma
disease surveillance
DNA methylation
Early Diagnosis
Epigenomics - methods
Gene expression
Gene Expression Profiling - methods
Gene Expression Regulation, Neoplastic
Genomics
Genomics - methods
Hematology, Oncology and Palliative Medicine
Humans
Kidney Neoplasms - diagnosis
Kidney Neoplasms - genetics
Kinases
Large-scale sequencing
metastasis
methylation
microRNA
miRNA
Mutation
patients
Prognosis
Rodents
Sensitivity and Specificity
sequence analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Majority of clear cell renal cell carcinomas (ccRCCs) are diagnosed in the advanced metastatic stage resulting in dramatic decrease of patient survival. Thereby, early detection and monitoring of the disease may improve prognosis and treatment results. Recent technological advances enable the identification of genetic events associated with ccRCC and reveal significant molecular heterogeneity of ccRCC tumors. This review summarizes recent findings in ccRCC genomics and epigenomics derived from chromosomal aberrations, DNA sequencing and methylation, mRNA, miRNA expression profiling experiments. We provide a molecular insight into ccRCC pathology and recapitulate possible clinical applications of genomic alterations as predictive and prognostic biomarkers.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2013.08.006